Align Technology heads into the week with a clear tension: a pronounced rebuilding of short positions against a broadly constructive analyst backdrop and a stock that, at $166.69, trades at a 20% discount to the average Street target.
Short sellers have been meaningfully more active. SI as a percentage of the free float has climbed to roughly 7% from about 5.8% a month ago — a 17% rise in positions over the past week alone, and up 16% over the past month. That move puts short interest at its highest level in the 30-day window and reverses what had looked like a gradual reduction through late April and early May. The jump was concentrated in the final week of May, with SI jumping from roughly 5.9% to 7% over just a few trading sessions.
The lending market tells a different story, and it is the most striking contradiction in the data. Borrow availability is extraordinarily loose — there are currently around 30 available shares in the lending pool for every one already borrowed, an availability ratio of over 3,000%. That figure has more than doubled from around 1,400% in late April, as lenders flooded supply into the market far faster than shorts could absorb it. Cost to borrow remains negligible at 0.53%. This is not a market under any squeeze pressure whatsoever; the borrow infrastructure for this stock is as accommodating as it gets. The rebuilding of short interest, then, reflects a directional view — not a technical crowding dynamic.
Options positioning is muted and barely worth flagging. The put/call ratio of 1.22 is almost exactly in line with its 20-day average of 1.21, with a z-score near zero. The 52-week range on the PCR runs from 0.76 to 1.61, so the current reading is close to the midpoint — neither defensive nor aggressively bullish. Options traders are not sending any particular message this week.
The analyst community has been directionally positive, and the recent activity is worth noting. Evercore ISI lifted its target to $220 in late April after maintaining its Outperform rating. Morgan Stanley moved its target up to $188 while holding at Equal-Weight. Citigroup initiated coverage in mid-April with a Buy and a $240 target — the most bullish print in the recent cohort. The mean consensus target of $209 implies roughly 25% upside from the current price, and that gap is the structural tension here: the Street broadly sees fair value well above where the stock is trading, yet SI has been rising. Something is pushing those two views apart. The bull case centres on Invisalign's near-monopoly in clear aligners, improving international volumes (particularly EMEA and APAC), and a forward EPS trajectory that has improved dramatically — the 12-month forward EPS estimate ranks in the 88th percentile for year-on-year improvement. The sceptic's argument is harder to locate in the data, but the 7% of float that is short clearly sees the stock's 7% decline over the past month as more than a buying opportunity.
Institutional ownership provides some context on whose hands hold the stock. Capital Research and Management, the largest holder, added over 1.75 million shares in the most recent reporting period, bringing its stake to 11.3% of the company — a meaningful vote of confidence. Goldman Sachs added 889,000 shares, and UBS Asset Management added 1.32 million. These are not passive flows: active managers were adding into a period when the stock was already under pressure. The only notable insider activity in the data is routine board award grants from May 20, all at $0 cost — nothing that adds or subtracts from the directional picture.
On valuation, the P/E multiple of 14.1x has compressed about 4% over the past 30 days, and EV/EBITDA at 9.1x has moved in the same direction. For a company with an estimated $4.2 billion in revenue and over $1 billion in EBITDA, those are not demanding multiples — which goes some way to explaining why larger institutional investors have been adding rather than cutting. The ORTEX short score of 44.6 sits in the 32nd percentile for the sector, meaning ALGN is not in the top tier of heavily-shorted names on a relative basis, despite the recent rate of change.
The next earnings event is scheduled for July 29. The most recent print in May produced a 5% one-day gain — the stock has moved modestly on results, with the May event the strongest reaction of the tracked history. What to watch between now and then is whether the short rebuild continues at its recent pace or plateaus as the stock stabilises, and whether the wide gap between the $166 price and the $209 consensus target narrows from below — through price — or from above, through target cuts.
See the live data behind this article on ORTEX.
Open ALGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
